Better Health for All

Dynavax's core business is 100% focused on developing and commercializing preventative vaccines for serious diseases like Hepatitis B, shingles, plague, Lyme disease, and pandemic influenza.

In Q1 2025, R&D expenses were $19.4 million, representing 28.45% of total revenues, demonstrating significant investment in health innovation. The company contributes to global health crisis response by developing a pandemic influenza vaccine adjuvant and by having its CpG 1018 adjuvant used in multiple COVID-19 vaccines, some with Emergency Use Authorization. HEPLISAV-B has a proven immunogenicity and safety profile , with a study showing no increased risk of acute myocardial infarction compared to another hepatitis B vaccine. Common patient-reported adverse reactions include injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%). Warnings are provided for severe allergic reactions and diminished immune response in immunocompromised individuals. The company provides comprehensive safety information for HEPLISAV-B, detailing common adverse reactions and warnings. However, a significant issue occurred when a third-party clinical trial site operator destroyed data for approximately half of the subjects in the HBV-24 study, leading to a Complete Response Letter from the FDA due to insufficient data, impacting both healthcare data responsibility and clinical trial ethics. The company generates no revenue from products with negative health outcomes and its business does not involve food/nutritional products or products with addiction potential.

Honest & Fair Business

Dynavax has reported no regulatory fines in the past three years and no financial restatements.

The company maintains comprehensive anti-corruption policies and training across all business areas, supported by a Chief Ethics and Compliance Officer and a dedicated Ethics and Compliance Steering Committee. It also has a Code of Business Conduct and Ethics setting clear expectations for responsible and transparent conduct.

No War, No Weapons

Dynavax Technologies Corporation reported $3.2 million in revenue from Department of Defense (DoD) contracts for the three months ended March 31, 2025.

This represents approximately 4.69% of its total revenue of $68.2 million. The company is collaborating with the U.S. Department of Defense to develop an adjuvanted plague vaccine using its CpG 1018 adjuvant, under a $22 million contract for a Phase II clinical trial. This vaccine technology has both civilian (public health) and military (biodefense) applications, indicating a dual-use technology. Given the company's primary focus on vaccine development, its R&D is considered to have a majority civilian focus, with the dual-use aspect evaluated on a case-by-case basis.

Planet-Friendly Business

Dynavax has not aligned with the Science Based Targets initiative (SBTi) and has no documented reduction targets or climate pledges.

The company has not publicly committed to a net-zero target year. Dynavax does not publicly report specific Scope 1, 2, or 3 carbon emissions data. While its headquarters is LEED Gold-certified and it has a recycling program, there is no information on the percentage of certified buildings or the waste diversion rate across all operations. No data is provided for renewable energy use, water use per revenue, or environmental compliance violations.

Respect for Cultures & Communities

The provided articles do not contain specific, quantitative evidence for any of the KPIs related to Respect for Cultures & Communities. The articles primarily focus on commercial partnerships for vaccine distribution

and general employee volunteer activities , without providing data on formal partnerships with indigenous or local community groups, revenue reinvested in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, FPIC processes, community governance inclusion, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license, charitable giving to cultural heritage, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training completion.

Zero Waste & Sustainable Products

The provided articles do not contain any quantitative data or specific facts relevant to the KPIs under the 'Zero Waste & Sustainable Products' ethical value.

Both articles explicitly state the absence of such data, therefore no KPIs can be scored based on the evidence provided.